News
POC FOR CYTOKINES
7:02 pm MST | Jun 8, 2018 | BioCentury | Product Development POC FOR CYTOKINES Cytokines are emerging as a logical combination partner to boost PD-1 responses by Emily Cukier, Senior...
read moreNantHealth and NantOmics to Present Patterns of Immune Checkpoint molecules in relation to pd-l1 expression at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based,...
read moreNantHealth and NantOmics to Present Data on Three-fold Overestimation of Tumor Mutation Burden Using Gene Panel vs Whole Exome at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based,...
read moreNantHealth and NantOmics to Share Data on Next-generation Sequencing of Paired DNA and RNA Analysis of Rare Tumors at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Results to be presented during the tumor biology session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based,...
read moreNanthealth and Nantomics to Present Data on the Frequency of Non-expressed Variants Tested by Standard NGS Panel at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Results to be presented during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting CHICAGO, IL – June 4, 2018 – NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a...
read moreNANT Receives FDA Authorization for New Clinical Trials with Personalized, Next-Generation Neoepitope Cancer Vaccine
The FDA has authorized a phase 1 study for an investigational Neoepitope Yeast Vaccine, YE-NEO-001, in patients previously treated for cancer CHICAGO – June 3, 2018 — NANT, a technology and research company connecting breakthrough research in biology,...
read moreNantOmics to Present Data for Mutational Processes and Response to Neoadjuvant Chemotherapy in Breast Cancer at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Genomic sequence analysis linked response to neoadjuvant therapy including Abraxane in triple negative breast cancer (TNBC) to a unique molecular signature. The results to be presented during the breast cancer session at ASCO 2018 Annual Meeting CHICAGO,...
read moreNantOmics to Report Data on Cardiac Function in Sarcoma Patients Receiving Aldoxorubicin with Doxorubicin Equivalent Doses Over 1000 mg/m2 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Results to be presented during the sarcoma session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 2, 2018 – NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks...
read moreNantOmics to Present Analysis on Potential Therapeutic Target in Adenoid Cystic Carcinoma at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
Results to be presented during the head and neck cancer session at the ASCO 2018 Annual Meeting CHICAGO, IL – June 2, 2018 – NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the...
read moreNantOmics Announces Study Showing Signature Analysis that Reveals Three Distinct Classifications of Skin Cancer Known as Sebaceous Carcinoma
May 21, 2018 Research published on May 14 in the peer-reviewed journal Nature Communications shows for the first time three distinct classifications of sebaceous carcinoma, a rare and sometimes deadly form of skin cancer. Culver City, CA – May 21, 2018...
read moreSNN: Breakthrough Cancer Treatment Targets Each Patient’s Unique Tumor
February 17, 2017
read moreGenos Names Four Research Partners, Launches Sequencing Platform
December 16, 2016 a GenomeWeb staff reporter NEW YORK (GenomeWeb) – Consumer genomics firm Genos announced yesterday named four of its research partners, which are using the company's newly launched whole-exome sequencing platform in various projects and...
read moreThe CLIA certification and CAP accreditation ensures the highest quality test results from the NantOmics lab to help improve cancer outcomes and will support the Cancer Cancer Breakthroughs 2020 mission in its war on cancer
CULVER CITY, Calif. – April 19, 2016 – NantOmics, LLC, the leader in molecular diagnostics and member of the NantWorks ecosystem of families, today announced that its laboratories have been certified by the U.S. Department of Health and Human Services'...
read moreNantOmics Announces Presentations at the 2015 San Antonio Breast Cancer Symposium
December 09, 2015 CULVER CITY, Calif.--(BUSINESS WIRE)--NantOmics, a leading molecular diagnostic company and a member of the NantWorks ecosystem of companies, today announced that three posters describing the molecular profiling of tumors from patients...
read moreNantOmics Acquires Oncoplex Diagnostics, An Accredited Proteomics Diagnostic Laboratory
LOS ANGELES, CA., September 10, 2015 LOS ANGELES – (Business Wire) – NantOmics, a leading molecular diagnostic company and a member of the NantWorks ecosystem of companies, today announced that it has acquired the remaining shares of privately owned...
read more